CD44 and neoplasm: We also estimated the overall survival according to tumor ESA/CD24/CD44 stemness: medians were 412 (104–720) days and 778 (335–1221) days for patient with HST (n = 20) or LST (n = 21), respectively (Log Rank, p = 0.58; Breslow p = 0.066; see Figure 5B).